Navigation Links
Capital BlueCross Acquires Dominion Dental
Date:11/4/2008

- Transaction adds 400,000 members and brings Blue branded dental plan to central Pennsylvania (Lehigh Valley) -

HARRISBURG, Pa., Nov. 4 /PRNewswire/ -- Capital BlueCross announced today that it is acquiring Dominion Dental Services, a privately held corporation headquartered in Alexandria, VA. The move by the region's leading health insurer adds nearly 400,000 members throughout the Commonwealth of Pennsylvania and the Mid-Atlantic Region.

"Helping to improve the health of our members is not limited to just medical care," said William Lehr, Jr., president and CEO of Capital BlueCross. "Good dental care improves the health and wellness of individuals and fits perfectly with our strategy to coordinate care across all health care services. This acquisition is part of our long-term strategy to remain the region's leading insurer by delivering innovative solutions and world-class service to our members at affordable prices."

Dominion currently offers dental benefit plans in Pennsylvania, Maryland, Delaware, Virginia, and Washington, DC. According to Mitch McGlynn, CEO of Dominion, "We've been serving the Mid-Atlantic region for more than a decade. It's a great opportunity for our company, our employees, and our customers."

Various regulatory approvals are required before the transaction can be finalized.

Capital BlueCross is the leading health insurer in its region, providing health benefits coverage to nearly one million people in central Pennsylvania and the Lehigh Valley. Capital BlueCross is committed to making health insurance simple for its customers and members through all the stages of life by offering nationally acclaimed customer service and a full range of innovative benefit programs and services.

The company has been providing health security to the people and communities of central Pennsylvania and the Lehigh Valley for 70 years and employs more than 2,300 people in the region.

Capital BlueCross is an
'/>"/>

SOURCE Capital BlueCross
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
4. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Advanced Life Sciences Joins NASDAQ Capital Market
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... for Dental Research (AADR) is presenting an honorary membership ... at the AADR/Research!America Advocacy Day, March 2, 2010, in ... his commitment to the National Institutes of Health (NIH) ... (NIDCR). He remains one of the Senate,s most staunch ...
... that reward workers for meeting certain performance measures for ... use a variety of methods to reward physicians financially ... A new study in the Journal for ... be effective in incentivizing low performing physicians. The article ...
... aimed at helping with planning efforts for a public ... the Harvard School of Public Health (HSPH) have found ... significant anthrax attack in their city or town, most ... obtain prophylactic antibiotics. However, a significant minority of those ...
... ... was featured in a national study of high performance services firms entitled “The High Growth ... , ... 2010 -- Webmarketing 123, a San Francisco Bay Area based search engine marketing firm, was ...
... suggests , FRIDAY, Feb. 19 (HealthDay News) -- In the ... identified a defective signaling pathway that contributes to the severity ... sticky mucus to build up in the lungs and digestive ... genetic diseases in children and young adults. , In the ...
... HRT use explain the trend, researchers say , FRIDAY, ... declining, especially among women over 50 who have estrogen ... the reason why. , After analyzing data on more ... that the decline may be linked with decreasing use ...
Cached Medicine News:Health News:AADR presents honorary membership to Senator Tom Harkin 2Health News:Poll: Hypothetical anthrax attack and antibiotics 2Health News:Poll: Hypothetical anthrax attack and antibiotics 3Health News:Poll: Hypothetical anthrax attack and antibiotics 4Health News:Poll: Hypothetical anthrax attack and antibiotics 5Health News:Poll: Hypothetical anthrax attack and antibiotics 6Health News:Webmarketing 123 Profiled in National Study of High Growth Professional Services Firms 2Health News:Webmarketing 123 Profiled in National Study of High Growth Professional Services Firms 3Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Dips in Breast Cancer Rates Seen Most in Affluent Women 2Health News:Dips in Breast Cancer Rates Seen Most in Affluent Women 3
(Date:1/23/2015)... Jan. 23, 2015 A lot of discussion in the ... treating  certain illnesses, injuries, or conditions. As medical science advances, ... methods with ones that they consider to be more cutting ... not one textbook method of treatment that stands out as ...
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... Fifth International Phase III ACTEMRA Study Meets its Primary ... today announced that two-year data from the LITHE (Toci ... Prevention of Structural Joint Damage) study demonstrated ... structural damage to joints in patients with rheumatoid arthritis ...
... Shire plc (LSE: SHP, Nasdaq: SHPGY ), the ... that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII ... (20 mg X 2), did not alter the median time ... to be reached in the subjects evaluated. In the ...
Cached Medicine Technology:Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients 2Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients 3Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients 4Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients 5Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Testing for Strabismus (ocular misalignment) just became easier. By simply placing the StrabismoScope over the patient's eye, the examiner is able to observe the occluded eye directly, but the patien...
The Welch Allyn 125 BIO is designed to achieve precise binocular viewing and stereopsis easier than ever before. Its observation paths can be adjusted from 48 mm to 74 mm to handle the widest and nar...
Patented coaxial optics, Halogen HPX illumination, and 68 focusing lenses combine for premium quality....
Medicine Products: